JP2023552468A - Ｒｎａの製造 - Google Patents

Ｒｎａの製造 Download PDF

Info

Publication number
JP2023552468A
JP2023552468A JP2023534907A JP2023534907A JP2023552468A JP 2023552468 A JP2023552468 A JP 2023552468A JP 2023534907 A JP2023534907 A JP 2023534907A JP 2023534907 A JP2023534907 A JP 2023534907A JP 2023552468 A JP2023552468 A JP 2023552468A
Authority
JP
Japan
Prior art keywords
rna
functional analog
triphosphate
utp
gtp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023534907A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023552468A5 (https=
JPWO2022122689A5 (https=
Inventor
ツィーゲンハルス，トーマス
クーン，アンドレアス
フェッサー，シュテファニー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biontech SE
Original Assignee
Biontech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech SE filed Critical Biontech SE
Publication of JP2023552468A publication Critical patent/JP2023552468A/ja
Publication of JP2023552468A5 publication Critical patent/JP2023552468A5/ja
Publication of JPWO2022122689A5 publication Critical patent/JPWO2022122689A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07006—DNA-directed RNA polymerase (2.7.7.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1247—DNA-directed RNA polymerase (2.7.7.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023534907A 2020-12-09 2021-12-07 Ｒｎａの製造 Pending JP2023552468A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063123465P 2020-12-09 2020-12-09
US63/123,465 2020-12-09
US202063132473P 2020-12-30 2020-12-30
US63/132,473 2020-12-30
PCT/EP2021/084488 WO2022122689A1 (en) 2020-12-09 2021-12-07 Rna manufacturing

Publications (3)

Publication Number Publication Date
JP2023552468A true JP2023552468A (ja) 2023-12-15
JP2023552468A5 JP2023552468A5 (https=) 2024-12-16
JPWO2022122689A5 JPWO2022122689A5 (https=) 2024-12-16

Family

ID=79287682

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023534907A Pending JP2023552468A (ja) 2020-12-09 2021-12-07 Ｒｎａの製造

Country Status (10)

Country Link
US (1) US20240110214A1 (https=)
EP (1) EP4259161A1 (https=)
JP (1) JP2023552468A (https=)
KR (1) KR20230129432A (https=)
AU (1) AU2021395736A1 (https=)
CA (1) CA3201552A1 (https=)
IL (1) IL303457A (https=)
MX (1) MX2023006126A (https=)
TW (1) TW202237844A (https=)
WO (1) WO2022122689A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ310613B6 (cs) 2020-09-23 2026-01-28 Ústav organické chemie a biochemie AV ČR, v. v. i. Lipidoidy pro transfekci nukleových kyselin a jejich použití
TW202306573A (zh) * 2021-05-26 2023-02-16 比利時商ｅＴｈｅＲＮＡ免疫治療公司 減少雙股ｒｎａ副產物形成的方法
CZ310443B6 (cs) 2021-07-19 2025-06-25 Ústav organické chemie a biochemie AV ČR, v. v. i. Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
JP2024534120A (ja) 2021-08-24 2024-09-18 ビオンテック・ソシエタス・エウロパエア インビトロ転写技術
CN121263517A (zh) * 2023-02-01 2026-01-02 美国金斯瑞公司 体外转录方法和用于其中的化合物
EP4705499A1 (en) * 2023-05-05 2026-03-11 TriLink BioTechnologies, LLC In vitro transcription method
WO2025170909A1 (en) * 2024-02-05 2025-08-14 The Broad Institute, Inc. Nucleic acids with region-specific modifications and methods of making the same
WO2025223684A1 (en) * 2024-04-23 2025-10-30 BioNTech SE Methods and compositions for stimulating immune response

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017517266A (ja) * 2014-06-10 2017-06-29 キュアバック アーゲー Ｒｎａ生成を強化する方法及び手段

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7839594A (en) 1993-09-20 1995-04-10 Regents Of The University Of Colorado, The Strategy for the production of rna from immobilized templates
US7074596B2 (en) 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
EP2049665A2 (en) 2006-07-28 2009-04-22 Applera Corporation Dinucleotide mrna cap analogs
WO2008157688A2 (en) 2007-06-19 2008-12-24 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
RU2013120302A (ru) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Сконструированные нуклеиновые кислоты и способы их применения
WO2013059475A1 (en) 2011-10-18 2013-04-25 Life Technologies Corporation Alkynyl-derivatized cap analogs, preparation and uses thereof
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
ES2964690T3 (es) 2015-09-21 2024-04-09 Trilink Biotechnologies Llc Método para sintetizar ARN con caperuza 5'
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
EP3882343A3 (en) 2016-01-13 2021-12-08 New England Biolabs, Inc. Thermostable variants of t7 rna polymerase
US10337051B2 (en) * 2016-06-16 2019-07-02 The Regents Of The University Of California Methods and compositions for detecting a target RNA
EP4599847A3 (en) 2016-10-25 2025-11-12 Trustees of Dartmouth College Prefusion coronavirus spike proteins and their use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017517266A (ja) * 2014-06-10 2017-06-29 キュアバック アーゲー Ｒｎａ生成を強化する方法及び手段

Also Published As

Publication number Publication date
WO2022122689A1 (en) 2022-06-16
CA3201552A1 (en) 2022-06-16
EP4259161A1 (en) 2023-10-18
AU2021395736A9 (en) 2024-05-16
IL303457A (en) 2023-08-01
AU2021395736A1 (en) 2023-07-27
US20240110214A1 (en) 2024-04-04
MX2023006126A (es) 2023-07-28
KR20230129432A (ko) 2023-09-08
TW202237844A (zh) 2022-10-01

Similar Documents

Publication Publication Date Title
JP2023552468A (ja) Ｒｎａの製造
US12480117B2 (en) Compositions comprising modified circular polyribonucleotides and uses thereof
EP3289101B1 (en) Immobilized poly(n)polymerase
JP2025061366A (ja) 安定化尾部領域を含むポリヌクレオチド
US12496561B2 (en) Vortex mixers and associated methods, systems, and apparatuses thereof
WO2024015890A1 (en) Norovirus mrna vaccines
US12305210B2 (en) In vitro transcription technologies
JP2023521800A (ja) 治療用ｍｒｎａのインビトロ製造及び精製
WO2020061397A1 (en) Compositions and methods for delivery of nucleic acids
US12215317B2 (en) Acetylated ribonucleic acids and uses thereof
CA3234214A1 (en) Methods for determining mutations for increasing modified replicable rna function and related compositions and their use
JP2021533826A (ja) 正確に改変した秘匿メッセンジャーｒｎａ、及び、その他のポリヌクレオチド
CN116744941A (zh) Rna制造
WO2025231018A2 (en) Therapeutic compositions and methods for producing and using the same

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241206

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250206

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260306